56 related articles for article (PubMed ID: 3839529)
1. Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate.
Joerger M; Ferreri AJ; Krähenbühl S; Schellens JH; Cerny T; Zucca E; Huitema AD
Br J Clin Pharmacol; 2012 Feb; 73(2):240-7. PubMed ID: 21838788
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology.
Zandvliet AS; Schellens JH; Beijnen JH; Huitema AD
Clin Pharmacokinet; 2008; 47(8):487-513. PubMed ID: 18611060
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia.
Aumente D; Buelga DS; Lukas JC; Gomez P; Torres A; García MJ
Clin Pharmacokinet; 2006; 45(12):1227-38. PubMed ID: 17112298
[TBL] [Abstract][Full Text] [Related]
4. Benefits of pharmacological knowledge in the design and monitoring of cancer chemotherapy.
Canal P; Gamelin E; Vassal G; Robert J
Pathol Oncol Res; 1998; 4(3):171-8. PubMed ID: 9761935
[TBL] [Abstract][Full Text] [Related]
5. Bayesian population pharmacokinetic and pharmacodynamic analyses using mixture models.
Rosner GL; Müller P
J Pharmacokinet Biopharm; 1997 Apr; 25(2):209-33. PubMed ID: 9408860
[TBL] [Abstract][Full Text] [Related]
6. Identification of patients with impaired hepatic drug metabolism using a limited sampling procedure for estimation of phenazone (antipyrine) pharmacokinetic parameters.
Fabre D; Bressolle F; Goméni R; Bouvet O; Dubois A; Raffanel C; Gris JC; Galtier M
Clin Pharmacokinet; 1993 Apr; 24(4):333-43. PubMed ID: 8491059
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics. Theory and clinical application.
Whiting B; Kelman AW; Grevel J
Clin Pharmacokinet; 1986; 11(5):387-401. PubMed ID: 3536257
[TBL] [Abstract][Full Text] [Related]
8. A limited sampling procedure for estimating adriamycin pharmacokinetics in cancer patients.
Launay MC; Milano G; Iliadis A; Frenay M; Namer N
Br J Cancer; 1989 Jul; 60(1):89-92. PubMed ID: 2803920
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Sawchuk-Zaske and Bayesian forecasting for aminoglycosides in seriously ill patients.
Denaro CP; Ravenscroft PJ
Br J Clin Pharmacol; 1989 Jul; 28(1):37-44. PubMed ID: 2775614
[TBL] [Abstract][Full Text] [Related]
10. Bayesian estimation of doxorubicin pharmacokinetic parameters.
Bressolle F; Ray P; Jacquet JM; Brès J; Galtier M; Donadio D; Jourdan J; Rossi JF
Cancer Chemother Pharmacol; 1991; 29(1):53-60. PubMed ID: 1742849
[TBL] [Abstract][Full Text] [Related]
11. Bayesian parameter estimation and population pharmacokinetics.
Thomson AH; Whiting B
Clin Pharmacokinet; 1992 Jun; 22(6):447-67. PubMed ID: 1587057
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Bayesian estimation in comparison to NONMEM for population pharmacokinetic data analysis: application to pefloxacin in intensive care unit patients.
Bruno R; Iliadis MC; Lacarelle B; Cosson V; Mandema JW; Le Roux Y; Montay G; Durand A; Ballereau M; Alasia M
J Pharmacokinet Biopharm; 1992 Dec; 20(6):653-69. PubMed ID: 1302767
[TBL] [Abstract][Full Text] [Related]
13. Bayesian estimation and prediction of clearance in high-dose methotrexate infusions.
Iliadis A; Bachir-Raho M; Bruno R; Favre R
J Pharmacokinet Biopharm; 1985 Feb; 13(1):101-15. PubMed ID: 3839529
[TBL] [Abstract][Full Text] [Related]
14. High-dose methotrexate: preliminary evaluation of a pharmacokinetic approach.
Monjanel S; Rigault JP; Cano JP; Carcassonne Y; Favre R
Cancer Chemother Pharmacol; 1979; 3(3):189-96. PubMed ID: 527209
[TBL] [Abstract][Full Text] [Related]
15. Test dose for predicting high-dose methotrexate infusions.
Kerr IG; Jolivet J; Collins JM; Drake JC; Chabner BA
Clin Pharmacol Ther; 1983 Jan; 33(1):44-51. PubMed ID: 6848298
[TBL] [Abstract][Full Text] [Related]
16. Bayesian estimation of methotrexate pharmacokinetic parameters and area under the curve in children and young adults with localised osteosarcoma.
Rousseau A; Sabot C; Delepine N; Delepine G; Debord J; Lachâtre G; Marquet P
Clin Pharmacokinet; 2002; 41(13):1095-104. PubMed ID: 12403645
[TBL] [Abstract][Full Text] [Related]
17. Adaptive control methods for the dose individualisation of anticancer agents.
Rousseau A; Marquet P; Debord J; Sabot C; Lachâtre G
Clin Pharmacokinet; 2000 Apr; 38(4):315-53. PubMed ID: 10803455
[TBL] [Abstract][Full Text] [Related]
18. Population kinetics and conditional assessment of the optimal dosage regimen using the P-PHARM software package.
Gomeni R; Pineau G; Mentré F
Anticancer Res; 1994; 14(6A):2321-6. PubMed ID: 7825966
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
